Key Takeaways:
- Syensqo launches strategic review for its Performance & Care segment
- The unit generated €2.0 billion in 2025 sales and €358 million in EBITDA
- Move aims to sharpen focus on high-growth aerospace and electronics markets
Key Takeaways:

Belgian chemical company Syensqo SA is launching a strategic review of its Performance & Care unit, a business that generated €2.0 billion in 2025 sales, as it pivots to become a pure-play specialty materials supplier for high-growth industries.
“Today’s announcement reflects our intention to further sharpen our portfolio, increase our focus on technologies where we see the strongest long-term growth opportunities and drive sustained, innovation-led differentiation,” Mike Radossich, Chief Executive Officer of Syensqo, said in a statement. “Accordingly, we will now evaluate a range of strategic options for the Performance & Care segment, with an emphasis on maximizing long-term value for our shareholders.”
The segment under review, which includes the Novecare and Technology Solutions business units, is a major producer of surface chemistry solutions and specialty mining reagents. It serves the consumer care, agriculture, coatings, and mining markets, reporting €358 million in underlying EBITDA for 2025. The review aligns with the company's goal to increase its exposure to structurally attractive end markets including aerospace, defense, electronics, and advanced mobility.
The move signals Syensqo's intent to streamline its operations and allocate capital more efficiently, a strategy often rewarded by investors seeking focused growth. A potential divestiture or spin-off of the Performance & Care unit could unlock significant shareholder value and allow for greater investment in advanced technologies, positioning Syensqo more directly against other specialty chemical giants focused on high-margin sectors. The company has not set a timetable for the review’s conclusion and said there is no certainty that a transaction will result. This article is for informational purposes only and does not constitute investment advice.